Abstract Biallelic germline mutations of MUTYH-a gene encoding a base excision repair protein-are associated with an increased susceptibility of colorectal cancer. Whether monoallelic MUTYH mutations also increase cancer risk is not yet clear, although there is some evidence suggesting a slight increase of risk. As the MUTYH protein interacts with the mismatch repair (MMR) system, we hypothesised that the combination of a monoallelic MUTYH mutation with an MMR gene mutation increases cancer risk. We therefore investigated the prevalence of monoallelic MUTYH mutations in carriers of a germline MMR mutation: 40 carriers of a truncating mutation (group I) and 36 of a missense mutation (group II). These patients had been diagnosed with either colorectal or endometrial cancer. We compared their MUTYH mutation frequencies with those observed in a group of 134 Dutch colorectal and endometrial cancer patients without an MMR gene mutation (0.7%) and those reported for Caucasian controls (1.5%). In group I one monoallelic MUTYH mutation was found (2.5%). In group II five monoallelic germline MUTYH mutations were found (14%), four of them in MSH6 missense mutation carriers (20%). Of all patients with an MMR gene mutation, only those with a missense mutation showed a significantly higher frequency of (monoallelic) MUTYH mutations than the Dutch cancer patients without MMR gene mutations (P=0.002) and the published controls (P=0.001). These results warrant further study to test the hypothesis of mutations in MMR genes (in particular MSH6) and MUTYH acting together to increase cancer risk.
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The MUTYH protein is a base excision repair (BER) DNA glycosylase that excises misincorporated adenines opposite 8-oxo-7,8-dihydro-2¢-deoxyguanosine (8-oxoG) , which is a product of oxidative DNA damage (Slupska et al. 1999) . Recently, it has been shown that having germline mutations in both copies (i.e. biallelic) of the MUTYH gene, increases the risk to develop multiple adenomatous polyps and, hence, colorectal cancer (Al Tassan et al. 2002) . Whether monoallelic MUTYH mutations also increase cancer risk is not yet clear, although there is some evidence suggesting a slight increase of risk (Croitoru et al. 2004; Farrington et al. 2005) . It is conceivable that germline monoallelic MUTYH mutations combined with germline mutations in other genes more strongly increase cancer risk.
Germline mutations of MLH1, MSH2 and MSH6 in combination with (functional) loss of the wild-type allele are known to cause a deficient DNA mismatch repair (MMR) system, and are responsible for hereditary non-polyposis colorectal cancer (HNPCC). HNPCC is one of the most common inherited cancer syndromes and is characterised by susceptibility to develop colorectal cancer and extracolonic malignancies, in particular endometrial cancer (Lynch and de la Chapelle 2003) . Gu et al. (2002) demonstrated that the MUTYH protein interacts with the MMR protein MSH6 which is part of the MSH2/MSH6 heterodimer (hMutSa). They showed that hMutSa stimulates the DNA binding and glycosylase activities of MUTYH. In addition, it was shown that the interaction between MUTYH and MSH6 was weaker in cells that expressed wild-type MSH2 and MSH6 missense mutations (Gu et al. 2002) . Considering this interaction between the MUTYH and MSH6 proteins, and assuming that part of (familial) cancer cases might be explained by combinations of lowpenetrant germline mutations in known hereditary cancer genes, we hypothesised that a monoallelic MUTYH mutation might contribute to cancer susceptibility in carriers of an MMR gene (in particular MSH6) mutation. This might be most apparent in the case of missense MMR gene mutations, that in contrast to truncating mutations, ''on their own'' may result in a less severely impaired MMR system and may therefore less strongly contribute to cancer risk.
As a first step to test this hypothesis, we investigated the prevalence of monoallelic MUTYH mutations in patients diagnosed with colorectal and/or endometrial cancer who carried a truncating or missense MMR gene mutation in MLH1, MSH2 or MSH6. We compared the frequencies of monoallelic MUTYH mutations in the two groups with that in a third group of patients, with colorectal and/or endometrial cancer without an MMR gene mutation and with the frequency of monoallelic MUTYH mutations reported for controls.
Materials and methods

Patient inclusion
In our study we included 210 unrelated colorectal and/or endometrial cancer patients (Table 1) . Each patient had recently been tested for germline MMR gene mutations in one of four different genetic centres, i.e. the University Medical Center Groningen (n=172), the Radboud University Nijmegen Medical Center (n=24), the Netherlands Cancer Institute in Amsterdam (n=5) and the Leiden University Medical Center (n=9), because they had an increased risk for HNPCC, e.g. early-onset cancer, multiple HNPCC associated tumours, or a positive family history for these tumours. Seventy-six patients had a proven germline mutation in one of the MMR genes MLH1, MSH2 and MSH6 (36 missense en 40 truncating mutation carriers) and 134 patients had no MMR gene mutation. All patients had given their informed consent and the study was approved by the Medical Ethical Committee of the University Medical Center Groningen, The Netherlands. MUTYH mutation frequency in control population Presently, no large groups of healthy Dutch controls have been screened for the entire MUTYH gene. Thus, the Dutch MUTYH mutation frequency is yet unknown. Therefore, data were taken from the only two studies in which the entire MUTYH gene of control individuals had been screened for mutations. Together, these studies reported 7 monoallelic MUTYH mutations in 461 controls from the British Isles [1.5% (95% CI 0.61-31)] (Sieber et al. 2003; Fleischmann et al. 2004 ).
Genetic analysis
For the mutation analysis in the MMR genes different techniques had been used: denaturing gradient gel electrophoresis (DGGE), single-strand conformational polymorphism analysis, direct sequencing and multiplex ligation dependent probe amplification, as described previously (Wu 1999; Gille et al. 2002) .
Mutation analysis of MUTYH in DNA from peripheral blood lymphocytes was performed for 201 patients by DGGE combined with direct sequencing of PCR fragments showing aberrant patterns in DGGE. polymerase chain reaction (PCR) was performed in a total reaction volume of 50 ll containing 200 ng of DNA, 15 pmol of each primer (Eurogentec, Serain, Belgium), 0.2 ll rTaq polymerase (5,000 U/ml, Amersham Pharmacia Biotech Inc., Biscataway, NY, USA), 5 ll DMSO (Sigma, Taufkirchen, Germany) and 5 ll PCR buffer (Amersham Biosciences, Roosendaal, Netherlands). The primer sequences are described in Table 2 .
A stepdown cycling regime was performed in an Applied Biosystems GeneAmp 9700 Thermal Cycler (Foster City, USA) using the following conditions: initial denaturation for 3 min at 94°C, followed by five cycles of 1 min at 94°C, 1 min at 60°C and 1 min at 72°C. Hereafter five more cycles with an annealing temperature of 57°C and 30 cycles with an annealing temperature of 54°C were performed. Finally, 5 min elongation at 72°C. PCR products were checked on a 2% agarose gel. PCR products with different melting temperatures were pooled in six different pools and PCR products were denaturated at 96°C for 10 min and reannealed at 50°C for 45 min before gel electrophoresis to encourage the formation of heteroduplex molecules. For DGGE analysis of MUTYH, a 30 ll pooled sample was applied onto a 1-mm-thick 9% polyacrylamide (PAA) gel (acrylamide:bisacrylamide=37.5:1) containing a denaturating gradient of 40-85% urea-formamide (100% urea-formamide contains 7 mol/l urea and 40% deionised formamide). Electrophoresis was performed in Microsatellite instability analysis MSI analysis was performed as described previously (Berends et al. 2002) . Cancers were classified as MSIhigh when two or more markers showed MSI and as MSI-low when one or no marker showed MSI. As a limited number of markers was analysed, the classification microsatellite-stable is not used.
Immunohistochemistry
Immunohistochemistry for the MLH1, MSH2 and MSH6 proteins was performed as previously described (Berends et al. 2002) Table 3 . In addition to the MUTYH mutations, several previously in the normal population described polymorphisms were detected. In the group of patients where MUTYH (n=201) was analysed by DGGE, the p.Val22Met (c.64G>A), p.Gln324His (c.972G>C) and p.Ser501Phe (c.1502C>T) polymorphisms were found with frequencies of 12.4%, 29.9%, and 3.0%, respectively. In addition, a silent mutation p.Tyr90Tyr (c.270C>T) was detected and various changes in non-coding sequences: c.36+75C>G
(0.5%), c.157+30A>G (6.5%), c.346+56G>A (1.0%), c.462+35G>A (10.4%), c.648+21C>A (1.0%), c.1145-27C>T (1.0%).
Discussion
In the present study we found a significantly higher frequency of monoallelic MUTYH mutations in (MSH6) missense mutation carriers than in published Caucasian controls and Dutch colorectal and endometrial cancer patients without MMR gene mutation.
We observed five different MUTYH mutations: four missense mutations, one splice site mutation. Of these, the p.Gly382Asp and p.Tyr165Cys missense mutations are the two most common pathogenic MUTYH missense mutations found in patients with multiple adenomatous polyps. The sequence change caused by the mutation c.36+1G>A interferes with the splice donor site and is considered pathogenic. For the two other missense mutations, p.Arg295Cys and p.Asp91Asn, no hard evidence for their pathogenicity is yet available. What we do know is that none of the mutations in this study was present in the 200 control chromosomes we examined. Furthermore, Sieber et al. (2003) reported the p.Arg295Cys mutation in a patient with three colorectal adenomas, and the p.Asp91Asn mutation has been reported once in a patient with colorectal cancer and 30 adenomas (Nielsen et al. 2005) , indicating that these two missense mutations might be pathogenic.
Of course one might also question the pathogenic nature of the four MMR missense variants that are found in combination with an MUTYH mutation. The MSH2 p.Ile577Thr and the MSH6 p.Pro1087Ser mutations have not been reported before, and we detected the latter in an other patient with colorectal cancer at age 36 (data not published). Alternative amino acid substitutions at this residue have been described (Wijnen et al. 1999 ) (http://www.insight-group.org). The pathogenicity of missense mutations is difficult to establish, even with help of functional assays. For example, Kolodner et al. performed a S. cerevisae-based assay to assess the pathogenicity of the MSH6 p.Ser144Ile missense mutation, and suggested that this mutation might be pathogenic (Kolodner et al. 1999 ). In contrast, in an in-vitro MMR assay that studied the ability of the mutant proteins to form MSH2-MSH6 heterodimers, the same MSH6 mutation appeared as functional as the wild type (Kariola et al. 2002) . Some mutations we found may eventually turn out to be harmless polymorphisms. For instance, the MSH6 p.Leu396Val mutation has been reported not only in cancer patients, but also in healthy controls (Wijnen et al. 1999) and was not considered pathogenic in a functional assay (Kolodner et al. 1999) . However, it is conceivable that a missense mutation on its own has little or no effect, but that it can significantly contribute to cancer risk in the presence of germline mutations in other genes.
We compared the MUTYH mutation frequency in the two groups of mutation carriers with the MUTYH mutation frequency in cancer patients without MMR mutation and with the 1.5% mutation frequency reported for controls. The MUTYH mutation frequency in the group of cancer patients without MMR mutation turned out to be not significantly different from the frequency in healthy British controls. In the former group, we expected the MUTYH mutation frequency to be similar or (somewhat) higher than in the normal British and Dutch population. Given the fact that there is presently no evidence to suggest a protective effect of MUTYH mutations against cancer, we have no reason to assume that the frequency in the normal Dutch population will be significantly higher than in Dutch cancer patients.
As co-occurrence of MMR gene missense mutations and MUTYH mutations might be a matter of chance, and considering the idea that probably most MSH6 (missense) mutations alone are not strongly promoting CRC development, one would expect the co-occurrence of both mainly in sporadic cancers. In fact, none of the five patients with a MUTYH and an MMR gene missense mutation were from an Amsterdam II positive family and two of the five patients had a negative first degree family history for HNPCC-associated tumours. One of the five patients with a MUTYH and an MMR gene missense mutation had an MSI-high tumour. Although this might suggest that MMR deficiency did not underlie tumour development in four of these five patients, three of these four patients carried a MSH6 mutation and pathogenic MSH6 germline mutations are known to be associated with lower rates of microsatellite instability than germline (Kolodner et al. 1999; Berends et al. 2002) . From a theoretical point of view, the MSH6 and MUTYH mutations might also have jointly impaired base-excision repair or impaired apoptosis signalling, a process that has been linked to MMR gene function (Fishel 2001) .
Our findings seem to be contradictory to the study recently published by Ashton et al. (2005) . They performed a similar study, in which they compared the MUTYH mutation frequencies in 233 MMR mutation negative and in 209 mutation positive HNPCC patients. They detected five heterozygous MUTYH mutations in the former and two in the latter group. There was no statistical difference in MUTYH mutation frequency between the two groups. However, we cannot compare their results with ours in all details, as for example, no MSH6 mutation carriers were included in their study, no subgroup analysis of truncating and missense MMR gene mutation carriers was presented, and instead of full MUTYH gene analysis, only the frequencies of the two most common mutations were determined.
In conclusion, we present the statistical observation that MUTYH mutations occur more frequently in MMR gene missense mutation carriers than in controls. Our preliminary results suggest that the presence of a monoallelic MUTYH mutation combined with a missense MMR gene mutation, of MSH6 in particular, leads to an increased cancer risk. As the possible interaction of the observed missense mutations is presently unknown at the functional level, we cannot reach any definite conclusions yet as to its clinical significance. However, if larger studies confirm these results, then this might have implications for management of patients with monoallelic MUTYH mutations. They should all be examined for mutations in MSH6 and conversely, MSH6 missense mutation carriers should all be screened for MUTYH mutations.
